Kura Oncology launches Caspian Therapeutics, targets clinical proof-of-concept for diabetes drug KO-7246 after USD 50 million financing
KURA•Preclinical data to be presented at EASD
Preclinical results were selected for future oral presentation at EASD on Sept. 29, 2026.
Animal and human islet studies showed improved insulin production and glycemic control, suggesting potential durable restoration of β-cell function.
Kura Oncology launches Caspian Therapeutics with USD 50 million financing
Kura Oncology launched Caspian Therapeutics with USD 50 million financing to advance KO-7246, a menin inhibitor for diabetes.
The funding targets IND-enabling work and initial clinical proof-of-concept, while Kura retains about half ownership on a fully diluted basis.
